We conclude that CSF levels of inflammatory markers are associated with clinical rating scales of motor and cognitive function as well as with levels of neurodegenerative CSF markers but that the majority of these inflammatory CSF markers is limited in robustly predicting longitudinal trajectories of developing cognitive impairment, at least in our two cohorts of PD patients with and without GBA mutation. This evidence concerns the gene GBA1 and Cognitive impairment.